What are your top takeaways from ASCO GU 2026?

• KEYNOTE-B15: Practice-changing study in mUC overturning prior SOC of several decades and establishing EVP as the new standard of care for patients with MIBC.
• RC48G001: Robust data for DV, a HER2-targeting ADC in treatment-refractory patients with mUC, supporting its use for a biomarker-defined patient population with HER2 expression.
• LITESPARK-022: Potential new adjuvant SOC in RCC with belzutifan and pembrolizumab.

I would highlight the NCI study of PSMA PET/CT monitoring of patients with biochemical relapse (Melissa Abel and Ravi Madan) and Johann de Bono's PSMA x CD3 bispecific.

The NCI study is one of the most thought-provoking in terms of what PSMA PET/CT findings may really mean, since no one has done a natural history study, and it underscores that PSMA PET+ scans are not the same as mCSPC.

The de Bono study is showing that immunotherapy is real and active even in heavily pre-treated patients.

I actuall...

1. Keynote-B15 -Neoadjuvant EV-Pembro in MIBC, Platinum-Eligible. This was the main practice-changing abstract at ASCO GU. In this phase 3 trial, 808 patients with MIBC, stage T1-4a N0-1 M0, were randomized to 4 cycles of neoadjuvant EV-P or GC chemotherapy followed by radical cystectomy and pelvic LND, and then adjuvant EV-P for 13 cycles every 3 weeks or observation. The primary endpoint of event-free survival was met (HR 0.53, p<0.0001) with 79% vs 66% of patients being event-free at 2 years. M...

• Ac225-PSMA-Trillium in mCRPC
• VIR-5500 in mCRPC
• Neoadjuvant EVP for MIBC
• Adjuvant pembro-belzutifan for RCC

• KEYNOTE-B15 - EV + Pembro vs Gem/Cis in MIBC. For the first time, an ADC–IO combination demonstrates superiority over long‑standing cisplatin‑based chemotherapy in cisplatin‑eligible muscle‑invasive bladder cancer. EV + Pembro will now be the standard of care for neoadjuvant therapy. A challenge that remains will be who will need the adjuvant therapy, as many patients will have a path CR and likely be able to avoid the adjuvant portion of the regimen. CtDNA will be key in helping decide who wou...